cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1068Research ArticleАРТЕРИАЛЬНАЯ ГИПЕРТОНИЯARTERIAL HYPERTENSIONОсновные результаты Российского исследования «АЛЬТАИР»Main results of the Russian trial «ALTAIR»ШляхтоЕ. В.ShlyakhtoE. V.КонрадиА. О.ConradyA. O.СвиряевЮ. В.SviryaevYu. V.ФГУ НИИ кардиологии им. В.А. Алмазова Росздрава. Санкт-ПетербургV.A. Almazov Research Institute of Cardiology, Russian Federal Agency of Health and Social Development. St. Petersburg200620022006512130Copyright © Шляхто Е.В., Конради А.О., Свиряев Ю.В., 20062006Шляхто Е.В., Конради А.О., Свиряев Ю.В.Shlyakhto E.V., Conrady A.O., Sviryaev Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1068

Представлены результаты многоцентрового, открытого, титрационного исследования рилменидина АЛЬТАИР (АЛЬбарел: эффекТивность и переносимость при Артериальной гИпеРтензии). Цель. Оценить антигипертезивную эффективность и безопасность терапии рилменидином в монотерапии и в комбинации с амлодипином у амбулаторных больных мягкой и умеренной артериальной гипертензией (АГ), его влияние на качество жизни, а также приверженность больных лечению. Материал и методы. В исследование были включены 677 больных, из них полностью без отклонений завершили протокол – 610 (90,4%), выбыли из исследования – 67 (9,6%). Длительность терапии составила 16 недель. Визиты осуществлялись на 4, 8, 12 и 16 неделях лечения. Результаты. Назначение рилменидина в дозе 1-2 мг/сут. больным АГ I-II степеней сопровождается достижением целевых значений АД в 46,6% случаев при хорошей переносимости лечения. Побочные эффекты терапии наблюдались у 11,9% больных, но только у 4,4% они потребовали отмены лечения и прекращения участия в исследовании. Комбинированная терапия рилменидином и амлодипином в дозе 2,5-5 мг/сут. сопровождалась увеличением числа «респондеров» до 87,5% на фоне отсутствия существенного роста побочных эффектов. Заключение. Результаты исследования АЛЬТАИР свидетельствуют о высокой эффективности рилменидина в монотерапии и в комбинации с амлодипином при хорошей переносимости лечения.

The results of the multi-center, open, titrating trial of rilmenidine «ALTAIR» (ALbarel: effectiveness and Tolerability in ArterIal hypeRtension) are demonstrated. Aim. To assess antihypertensive effectiveness and safety of rilmenidine as monotherapy and in combination with amlodipine in out-patients with mild to moderate arterial hypertension (AH), to investigate its effects on quality of life and treatment compliance. Material and methods. The study involved 677 patients: 610 participants (90.4%) completely fulfilled the protocol, and another 67 (9.6%) dropped out. Therapy lasted for 16 weeks. Clinical visits were performed at Week 4, 8, 12 and 16 of the treatment. Results. Rilmenidine (1-2 mg/d) therapy in Stage I-II AH was associated with BP target level achievement in 46.6% of the cases, with good therapy tolerability. Adverse events were registered in 11.9% of the participants, but treatment discontinuation and study termination was necessary in 4.4% of the subjects only. Combination of rilmenidine and amlodipine (2.5-5 mg/d) resulted in responder percentage increase to 87.5%, with simultaneous increase in adverse event rates, though. Conclusion. ALTAIR trial results demonstrated high effectiveness and good tolerability of rilmenidine treatment, as monotherapy or in combination with amlodipine.

артериальная гипертензиярилменидинамлодипинисследование АЛЬТАИРArterial hypertensionrilmenidineamlodipineALTAIR trialReferencesTatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.Lindholm LH, Ibsen T Dahlof B, еt al. Cardiovascular morbidity and mortality in patents with diabetes in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 1004-10.Lindholm LH, Ibsen T Dahlof B, еt al. Cardiovascular morbidity and mortality in patents with diabetes in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 1004-10.Bousquet P. Сentral cardiovascular effects of alpha-adrenergic drugs: differences between chatecholamine and imidazolines. J Pharmacol Exp Ter 1984; 230: 232-6.Bousquet P. Сentral cardiovascular effects of alpha-adrenergic drugs: differences between chatecholamine and imidazolines. J Pharmacol Exp Ter 1984; 230: 232-6.Guynet PG. Do imidazoline binding sites play a role in the efficacy of clonidine and related centrally acting antihypertensive drugs? Am J Physiol 1997; 273: R1580-4.Guynet PG. Do imidazoline binding sites play a role in the efficacy of clonidine and related centrally acting antihypertensive drugs? Am J Physiol 1997; 273: R1580-4.Ernsberger P, Haxhiu MA. The I1-imidazoline binding site is also functional receptor mediating vasodepression vie the ventral medulla. Am J Physiol 1997; 273: R1572-9.Ernsberger P, Haxhiu MA. The I1-imidazoline binding site is also functional receptor mediating vasodepression vie the ventral medulla. Am J Physiol 1997; 273: R1572-9.Bousquet P, Dontenwill M, Greney H, Feldman J. Imidazoline Receptors in Cardiovascular and Metabolic Diseases. J Cardiovasc Pharmacol 2000; 35(Suppl. 4): 21-5.Bousquet P, Dontenwill M, Greney H, Feldman J. Imidazoline Receptors in Cardiovascular and Metabolic Diseases. J Cardiovasc Pharmacol 2000; 35(Suppl. 4): 21-5.Krentz AJ, Evans AJ. Selective Imidazoline Receptors Agonists for Metabolic Syndrome. Lancet 1998; 351: 152-4.Krentz AJ, Evans AJ. Selective Imidazoline Receptors Agonists for Metabolic Syndrome. Lancet 1998; 351: 152-4.Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298: 1152-7.Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298: 1152-7.Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Артер гиперт 2000; 7/1, приложение.Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Артер гиперт 2000; 7/1, приложение.Koldas L, Ayan F, Ikitimur B. Short term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension. Jpn Heart J 2003; 44: 693-704.Koldas L, Ayan F, Ikitimur B. Short term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension. Jpn Heart J 2003; 44: 693-704.Farsang C, Lengyel M, Borbas S, et al. Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS). Curr Med Res Opin 2003;19(3): 205-17.Farsang C, Lengyel M, Borbas S, et al. Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS). Curr Med Res Opin 2003;19(3): 205-17.Sadowski Z, Azweld H, Kuch-Wocail, et al. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled study. J Hypertens 1998; 16(Suppl. 3): S29-35.Sadowski Z, Azweld H, Kuch-Wocail, et al. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled study. J Hypertens 1998; 16(Suppl. 3): S29-35.Anichkov DA, Shastak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipids and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res 2005; 21: 113-9.Anichkov DA, Shastak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipids and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res 2005; 21: 113-9.Небиеридзе Д.В. Рилменидин – один из первых представителей агонистов имидазолиновых рецепторов: новые возможности лечения артериальной гипертензии. Артер гиперт 2002; 8(4): 147-50.Небиеридзе Д.В. Рилменидин – один из первых представителей агонистов имидазолиновых рецепторов: новые возможности лечения артериальной гипертензии. Артер гиперт 2002; 8(4): 147-50.Beau B, Mahieux F, Paraire M, et al. Efficacy and safety of rilmenidine for arterial hypertension. Am J Cardiol 1988; 61(7): 95D-102.Beau B, Mahieux F, Paraire M, et al. Efficacy and safety of rilmenidine for arterial hypertension. Am J Cardiol 1988; 61(7): 95D-102.Luccioni R. Efficacy and Acceptability of Rilmenidine in 18235 Patients over One Year. Presse Med 1995; 124: 1827-64.Luccioni R. Efficacy and Acceptability of Rilmenidine in 18235 Patients over One Year. Presse Med 1995; 124: 1827-64.

The authors declare that there are no conflicts of interest present.